

BACKGROUND: Allergic inflammatory responses are driven by cells of the immune system that rely on cytokines to regulate the activity of other immune and structural cells.

Objective: To review published studies to (1) identify cytokines consistently increased after allergen challenge in atopic patients and (2) investigate temporal variation in cytokine expression.

Methods: A PUBMED systematic search was used to extract data from studies involving analysis of cytokine expression in fluids or biopsies following *in vivo* allergen challenge in atopic patients.

Results: Data were extracted from 82 studies. There were no consistent reports of cytokine protein increase in fluids of patients at 0–1 h after challenge. At 4–12 h, the chemokines cotaxin, macrophage inflammatory protein-1 α , RANTES (regulated on activation normal T cell expressed and secreted) and interleukin (IL)-8 have all been consistently reported to be up-regulated. At 18–24 h after challenge, the lymphokines IL-4, IL-5 and IL-13, as well as the pro-inflammatory cytokines granulocyte-macrophage colony-stimulating factor, tumour necrosis factor- α and IL-6 are consistently increased when compared with the respective control value. There were no reports of up-regulation in interferon- γ protein and mRNA and in IL-2 mRNA.

Conclusion: The expression of granulocyte-macrophage colony-stimulating factor is consistently increased in tissues at 4–12 h after challenge. The influence of this cytokine on antigen capture and presentation by dendritic cells should be further investigated. Additionally, allergen challenge studies are needed that investigate the expression of macrophage-derived chemokine and thymus-regulated and activation-regulated chemokine in tissues of atopic patients. Blocking the effects of these lymphocyte-specific chemokines might provide new therapeutic approaches for the control of allergic inflammation.

Key words: Allergen challenge, Cytokine, Inflammation, Allergy

Cytokine expression in allergic inflammation: systematic review of *in vivo* challenge studies

Manuel A. R. Ferreira^{CA}

Queensland Institute of Medical Research, P.O. Royal Brisbane Hospital, Brisbane 4029, Australia

^{CA}Corresponding author

Tel: +61 7 3845 3572

Fax: +61 7 33620101

E-mail: manuelF@qimr.edu.au

Introduction

Allergic reactions result from an inappropriate response of the immune system towards a group of non-self-molecules collectively termed allergens.¹ This over-reaction of specific defence mechanisms invariably triggers an inflammatory response that in some cases can cause debilitating secondary effects such as asthma.² Allergic inflammatory responses involve both cells of the immune system and structural cells of the injured tissue. To efficiently restore homeostasis, the activity of these cells must be integrated and coordinated. To a great extent, this coordination involves cellular communication via cytokine release.

Cytokines are extracellular signalling proteins produced by different cell types that act on target cells to modulate diverse cellular functions.³ Some cytokines

recruit specific cell types to the site of inflammation.⁴ Others can act on immune cells to increase activation and survival,^{5,6} whereas some, like interferon (IFN)- γ , suppress cellular activity.⁷ The role of cytokines in mounting an adequate immune response is further supported by the ability of lymphokines like interleukin (IL)-4 and IL-13 to induce immunoglobulin isotype switch in B cells^{8,9} and to modulate T-cell differentiation.¹⁰ Therefore, identifying the pattern of cytokine expression observed during the development of an allergic inflammatory response provides a valuable insight to the underlying immunological mechanisms.

Bronchial, nasal and cutaneous allergen challenge tests have been extensively used as a means of investigating allergen-induced inflammation.¹¹ Since the first studies published in 1991,^{12,13} literally hundreds of trials have investigated cytokine profile

following *in vivo* allergen challenge. In some cases, conflicting results have been reported. This review summarises data from these studies addressing the following questions: Which cytokines are consistently up-regulated in allergen challenged tissues of atopic patients? Is there a time-dependent pattern of cytokine expression? Finally, we discuss how these results can be used to improve the understanding and the control of allergic diseases.

Methods

Literature search

The PUBMED database was searched using the query “(allergen) AND (biopsy OR biopsies OR lavage* OR fluid* OR section*) AND (interleukin* OR IL- OR cytokine* OR chemokine* OR lymphokine*)”, using the limits Text Word, English and Human. This query was performed in May 2002 and returned 292 titles and/or abstracts.

Literature selection

The abstracts of these 292 articles were screened for provisional inclusion in this review. Articles were dropped from further analysis if they clearly did not involve: (1) human subjects, (2) allergen challenge *in vivo* and (3) collection of bronchial, nasal or cutaneous biopsies and/or fluids; review articles were also eliminated at this step. This procedure yielded 147 articles,^{12–158} of which five could not be obtained in full text format.^{154–158} The full text of the remaining 142 articles was screened to identify studies that included clinical trials involving: (i) the criteria (1)–(3) described earlier, (ii) a cytokine baseline or control value for each subject, and (iii) appropriate cytokine quantitative data. This procedure resulted in 107 relevant studies^{12–118} that were used for data extraction. The main criterion for exclusion in this last step was the absence of the aforementioned (iii) (51%). Inappropriate data commonly resulted from the absence of statistical comparison between baseline or control cytokine values and the post-allergen challenge value.

Data extraction

Several variables were extracted to characterise the subjects and the clinical trial used in each of the 107 selected studies. These included number, disease and atopy status of subjects challenged with allergen and, to characterise the trial design, the challenge site (lung/nose/skin), the allergen used, the specimen collected (biopsy/fluid), the control used (baseline/saline) and the time point of specimen collection after the allergen challenge (0–1 h/4–12 h/18–24 h).

In addition to these descriptive variables, the following information for each cytokine analysed was also extracted: control and post-allergen cytokine quantification, method for quantification and significance of the variation (*p* value).

Data analysis

Analysis was restricted to patients; data from healthy control subjects were not sufficient to allow proper analysis. Data from patients undertaking immunotherapy or corticosteroid treatment were also discarded. Each study contributed data more than once to the analysis if it involved: (a) two or more independent subject samples, (b) both biopsy and fluid collection per subject sample, (c) two or more cytokines analysed per specimen, or (d) for a given cytokine, a specimen collected at two or more time points after allergen challenge. When more than one specimen was collected and analysed for the same time point (e.g. report of cytokine level at 6 and 8 h after allergen challenge), the largest of the values was selected. This approach resulted in 358 contributions extracted from 82 published articles.

Of these 358 contributions, 205 reported a significant positive variation of the cytokine level when comparing the post-allergen value with the control value. By contrast, 149 articles reported no significant variation and four reported a significant negative variation. Therefore, the two latter categories were collapsed into one category (no increase) for statistical analysis.

This review does not involve a meta-regression analysis. Rather, it provides a convenient summary of studies that addressed similar questions using similar study designs. To complement such a summary, a binomial test for proportions was calculated to assess the likelihood of obtaining the observed cytokine data (i.e. number of studies reporting a significant positive variation versus number of studies reporting no increase) given an expected value predicted by the null hypothesis (H_0). The H_0 was that the allergen challenge had no effect on the cytokine level when compared with the control. This H_0 was translated into the binomial probabilities of 0.05 (*p*, probability of success) and 0.95 (*q*, probability of no success). An observed set of cytokine data was considered to be unlikely to occur under the H_0 if the probability value resulting from the binomial test for proportions was < 0.001 .

Results

Data description

Data reported here refer to 358 contributions extracted from 82 articles (mean contribution per

article, four). These 358 contributions were relatively uniform with respect to the atopy status of the patients and the allergen used for challenge. Indeed, 98% involved a sample of atopic subjects and 91% used a common allergen for challenge (grass, ragweed, birch, dust mite or pet extract). In addition to the allergen type, the allergen concentration used for challenge is known to affect the consequent severity of the inflammatory response. However, there was no consistent report of standardised values of allergen concentration, which prevented such analysis. The post-allergen cytokine value was compared with the baseline or saline challenge value in 39% and 61% of the cases, respectively. The studies reviewed here involved on average 10 subjects per trial (range, 4–35 subjects).

The 358 contributions included 200 fluid and 158 biopsy analyses. Ninety-one per cent and 84% of these analysed cytokine protein level by immunoassays (mostly enzyme-linked immunosorbent assay) and cytokine mRNA by *in situ* hybridisation, respectively. The remaining contributions involved different methods (e.g. immunohistochemistry) and, therefore, were not used for subsequent analysis.

Cytokine protein expression in fluids

Studies that assessed free protein levels in fluids provided quantitative data for 20 cytokines. However, for only 13 cytokines was the sample size (i.e. number of contributions) large enough to assure sufficient power to reject the null hypothesis (power ≥ 0.9). Summary data for these cytokines, as well as the references that provided the information, are presented in Table 1.

Four points should be noted. First, there are eight cytokines for which expression was analysed within 0–1 h after allergen challenge. For all these, no consistent positive variation was reported. Second, six cytokines appear to be consistently up-regulated in fluids at 4–12 h after challenge. Four of these are chemokines (eotaxin, macrophage inflammatory protein (MIP)-1 α , RANTES (regulated on activation normal T cell expressed and secreted) and IL-8). Third, 18–24 h after challenge, the lymphokines IL-4, IL-5 and IL-13, as well as the pro-inflammatory cytokines granulocyte–macrophage colony-stimulating factor (GM-CSF), tumour necrosis factor (TNF)- α and IL-6 are consistently increased compared with the respective control value. Finally, there was no evidence that IFN- γ is increased after challenge, whereas two studies demonstrated a significant IL-2 increase. Cytokines reported by a small number of studies ($n \leq 2$) are not presented in Table 1; these include monocyte chemotactic protein (MCP)-1,^{45,118} MCP-3,²⁵ macrophage-derived chemokine (MDC) and thymus-regulated and activation-regulated che-

mokine (TARC),¹⁶ transforming growth factor- α ,⁶⁵ IL-1 α ,³⁹ and IL-16.^{58,92}

Cytokine mRNA expression in biopsies

Most studies analysing cytokine mRNA in biopsies quantified the number of mRNA-positive cells per area of allergen-challenged tissue. This was usually conducted 18–24 h after challenge (Table 2). Of special interest is the consistent report of significant increases in mRNA positive cells for GM-CSF, IL-4, IL-5 and IL-3 and, by contrast, the systematic reports of no variation in IL-2 and IFN- γ . The expression of IL-10 and IL-13 mRNA was also shown to be up-regulated by independent studies. Cytokines not presented in Table 2 due to small sample size include eotaxin,^{20,69} MCP-3,¹¹¹ MIP-1 α ,¹¹⁴ RANTES, IL-6 and IL-8,^{54,55} IL-12,¹⁰⁹ and IL-16.⁶⁰

Discussion

This systematic review provides a summary of the published data reporting cytokine expression following allergen-induced tissue inflammation. It aimed to address two questions: Which cytokines are consistently up-regulated in fluids or biopsies of allergen challenged tissues in atopic patients? Is there a time-dependent pattern of cytokine expression? Here, we will point out how this knowledge can be used to improve the understanding and the control of allergic diseases.

First, no evidence could be found that cytokines are consistently increased within 0–1 h after allergen challenge. Within this period atopic subjects are known to experience an immediate hypersensitive response, which is driven to a great extent by mast cells and results in considerable tissue damage.¹⁵⁹ Since mast cells are known to release preformed inflammatory cytokines upon activation,^{160,161} it is to some extent surprising that no cytokine was observed to be consistently up-regulated within 0–1 h after challenge.

Second, this review confirms previous individual reports that the chemotactic cytokines eotaxin, MIP-1 α , RANTES and IL-8 are increased at a time point that corresponds to the onset of the late phase allergic reaction (4–12 h; see reference 11). Third, the inflammatory cytokines GM-CSF, TNF- α and IL-6, and the lymphokines IL-3, IL-4 and IL-5 are found to be significantly increased across a large number of independent studies at 18–24 h. Finally, IFN- γ protein and mRNA, and IL-2 mRNA have not been reported to be increased by any of the studies here reviewed. Although an attempt has been made to avoid labelling cytokines as Th1-like or Th2-like, the combined results presented here agree with the Th2

Table 1. Variation of cytokine protein levels in fluids collected after allergen challenge in atopic patients.

	Positive variation [†] n/N	Disease status [‡] asthma\rhinitis\other	Challenge site [§] Lung\nose\skin	References
Eotaxin				
4–12 h	4\6*	2\2\2	2\2\2	20,26,34,62,76,92
GM-CSF				
0–1 h	1\7	2\5\0	2\5\0	39,49,63,64,89,101
4–12 h	5\8*	1\5\2	0\5\3	33,34,63,66,76,89
18–24 h	7\9*	9\0\0	8\1\0	12,33,42,49,65,70,101,108
IFN- γ				
18–24 h	0\3	3\0\0	3\0\0	65,101,102
MIP-1 α				
4–12 h	3\3*	1\1\1	1\2\0	26,45,89
RANTES				
0–1 h	1\3	0\1\2	0\2\1	76,89,92
4–12 h	5\6*	2\1\3	2\3\1	26,45,89,92,95,118
18–24 h	2\3	2\0\1	2\1\0	26,45,90
TNF- α				
0–1 h	1\4	1\3\0	1\3\0	17,39,101
4–12 h	0\3	0\2\1	0\2\1	39,118
18–24 h	6\6*	5\1\0	5\1\0	42,70,88,101,102
IL-1 β				
0–1 h	1\3	1\2\0	1\2\0	64,89,101
18–24 h	2\4	4\0\0	4\0\0	42,70,101
IL-2				
18–24 h	2\3	2\1\0	2\0\1	61,65,101
IL-4				
0–1 h	0\4	3\1\0	3\0\1	35,49,56,101
4–12 h	3\3*	0\3\0	0\1\2	35,76,104
18–24 h	7\10*	8\2\0	8\2\0	42,41,44,56,65,70,88,101,102,104
IL-5				
0–1 h	1\5	2\2\1	3\2\0	49,51,63,92,101
4–12 h	3\6	2\3\1	2\3\1	34,43,63,82,92,93
18–24 h	10\12*	10\2\0	10\2\0	42,49,52,65,70,82,88,90,93,101,102
IL-6				
0–1 h	1\4	1\2\1	1\2\1	39,101,118
4–12 h	3\6	1\4\1	0\4\2	33,39,61,104,118
18–24 h	6\6*	5\1\0	4\2\0	33,42,70,101,104
IL-8				
0–1 h	1\9	2\4\3	3\5\1	38,48,74,89,101,105,118
4–12 h	7\11*	4\4\3	3\7\1	53,38,48,74,80,82,89,96,118
18–24 h	4\8*	7\1\0	5\3\0	33,42,70,80,82,96,101
IL-13				
18–24 h	3\3*	3\0\0	3\0\0	47,56,102

Each study involved both a control and a post-allergen challenge protein assay. The latter was performed in fluids collected 0–1 h, 4–12 h or 18–24 h after challenge. The number of studies (i.e. contributions, since some studies involve more than one subject sample; see Material and methods for details) reporting a significant higher level of protein after challenge when compared with the control value is represented by *n*.

† Number of studies (*n*) reporting a significant positive variation of cytokine level following allergen challenge. N: total number of studies reporting cytokine data.

‡ Number of studies involving patients with asthma, rhinitis or other diseases.

§ Number of studies involving allergen challenge in the lung, nose or skin.

* $p < 0.001$, binomial test for proportions (see Methods and methods for details).

profile claimed by many to be involved in asthma or other allergic diseases.

How can the conclusions from these studies be used to improve the understanding and control of allergic reactions?

Allergen challenge studies and the immunobiology of allergic reactions

Different studies have highlighted the fact that inflammatory cytokines are significantly increased in tissues exposed to allergen. These could be considered the danger messages used by cells of the immune system to sense a break in homeostasis. One of such cytokines identified by allergen challenge studies is GM-CSF. This cytokine is secreted by

a variety of cells, including T cells, macrophages and structural cells of the injured tissue.^{162,163} It acts pleiotropically with effects on target cells that include proliferation and differentiation of haematopoietic cells and activation of eosinophils.^{164,165} Importantly, GM-CSF has recently been shown to stimulate the functional maturation and activation of dendritic cells (DC) *in vivo*.^{166,167} Together, these findings might provide an important insight to the understanding of the immunobiology of allergic reactions. Indeed, DC are essential in the control of immunity.¹⁶⁸ Although subject to considerable research at present,¹⁶⁹ the maturation state of DC at the time of antigen presentation to T cells in the lymph nodes seems to be a key step that determines whether the organism will develop tolerance or immunity against self-

Table 2. Variation of cytokine mRNA expression in biopsies collected after allergen challenge in atopic patients.

	Positive variation [†] n/N	Disease status [‡] asthma\rhinitis\other	Challenge site [§] lung\nose\skin	References
GM-CSF				
18–24 h	7\7*	2\2\3	1\4\2	15,30,32,72,79,91,100
IFN- γ				
0–1 h	0\3	0\2\1	0\2\1	54,55,99
18–24 h	0\10	1\4\5	1\6\3	15,30,32,54,55,68,72,99,100,112
TNF- α				
18–24 h	2\4	0\2\2	0\3\1	54,55,115
IL-2				
0–1 h	0\3	0\2\1	0\2\1	54,55,99
18–24 h	0\8	1\2\5	1\5\2	15,30,32,54,55,68,99,100
IL-3				
18–24 h	5\7*	2\2\3	1\4\2	15,30,32,54,55,91,100
IL-4				
0–1 h	1\3	0\2\1	0\2\1	54,55,99
4–12 h	4\5*	2\1\2	1\1\3	14,43,78,99,110
18–24 h	15\18*	4\5\9	2\9\7	14,15,24–32,37,54,55,68,72,77,91,99,100,110,112,116
IL-5				
0–1 h	1\3	0\2\1	0\2\1	54,55,99
4–12 h	2\4	2\1\1	1\1\2	14,43,78,99
18–24 h	10\13*	3\5\5	1\7\5	14,15,30,32,54,55,68,72,91,99,100,112,117
IL-10				
0–1 h	2\3	1\2\0	0\2\1	54,55,87
IL-13				
18–24 h	2\4	0\3\1	0\4\0	36,54,55,72

Cytokine mRNA expression was assessed by *in situ* hybridization. Each study compared the number of positive cells observed in biopsies taken after challenge with the respective value observed in the control biopsy.

[†] Number of studies (*n*) reporting a significant positive variation of cytokine level following allergen challenge. N: total number of studies reporting cytokine data.

[‡] Number of studies involving patients with asthma, rhinitis or other diseases.

[§] Number of studies involving allergen challenge in the lung, nose or skin.

* $p < 0.001$, binomial test for proportions (see Methods and methods for details).

molecules and non-self-molecules.^{169,170} DC mature in peripheral tissues that secrete GM-CSF in response to injury. Therefore, it is plausible that the stimulation that DC receive *in situ* from this cytokine is a crucial step that determines the efficiency of these cells to prime antigen-specific immune responses. Importantly, the antigen presentation ability of DC might not only be a function of the GM-CSF concentration present in the microenvironment where it captured antigen, but also a function of the GM-CSF receptor allele that the cell expresses. This hypothesis has recently received some support from patients with lupus erythematosus. Indeed, dysregulation of the GM-CSF receptor in antigen presenting cells was found to be associated with a down-regulation of the CD80 costimulatory antigen.¹⁷¹ This could in turn lead to a dysfunction of antigen presentation to T cells. Although the GM-CSF receptor has been implicated in lung homeostasis,^{172–174} its role in the development of primary immune responses is still largely unknown.

Allergen challenge studies and the control of allergic reactions

Allergen challenge studies have demonstrated that chemotactic cytokines and lymphokines are significantly increased as a result of allergen challenge. Chemokines, such as eotaxin and MIP-1 α , are re-

leased by immune and structural cells of the injured tissue^{175,176} and are responsible for the late recruitment of eosinophils, neutrophils and basophils to the site of inflammation.^{177,178} This recruitment is an essential step in the development of the late-phase allergic response and, therefore, it represents a candidate immunological mechanism to be targeted by new therapeutical approaches. On the contrary, MDC and TARC are potent attractants of polarised Th2 cells.^{179,180} Although the ‘Th2 hypothesis’ for asthma or other allergic diseases is likely to be too simplistic,^{181,182} efficiently blocking the effects of these cytokines could represent a plausible approach to reduce the up-regulation of lymphokines such as IL-4, IL-5 and IL-13. Therapeutic approaches involving blocking antibodies against specific cytokines characteristic of allergic reactions have recently been reported. Indeed, the injection of a monoclonal antibody to IL-5 in allergic asthmatic volunteers significantly reduced the number of eosinophils in blood and sputum.¹⁸³ Although no changes were observed in the magnitude of the late-phase response, this clearly demonstrated that efficient *in vivo* blockage of cytokine effects in allergic asthmatics can drastically influence specific immunological mechanisms.

This review confirms that inflammatory cytokines such as GM-CSF, TNF- α and IL-6 are increased in tissues of atopic patients exposed to allergen. There-

fore, the ability of these cytokines to modulate antigen capture and antigen presentation *in vivo* by DC should be further investigated. In addition, it is also shown that different lymphocyte-derived cytokines are significantly increased after allergen challenge. Thus, the development of new strategies for allergic disease control should consider the effects of blocking chemokines that target specific lymphocyte subtypes, such as MDC or TARC. Data concerning the expression of these chemokines following allergen exposure is scarce and, therefore, should be addressed by future allergen challenge studies.

ACKNOWLEDGEMENTS. Invaluable suggestions were provided by Anne Kelso, David Duffy and Nick Martin. M.A.R.F. is supported by the grant SFRH/BD/4824/2001 from the Fundação para a Ciência e Tecnologia, Portugal.

References

- Johansson SG, Hourihane JO, Bousquet J, *et al.* A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. *Allergy* 2001; **9**: 813–824.
- Holt PG, Macaubas C, Stumbles PA, Sly PD. The role of allergy in the development of asthma. *Nature* 1999; **6760 (Suppl)**: B12–B17.
- Chung KF, Barnes PJ. Cytokines in asthma. *Thorax* 1999; **9**: 825–857.
- Ponath PD, Qin S, Ringler DJ, *et al.* Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. *J Clin Invest* 1996; **3**: 604–612.
- Yamaguchi Y, Hayashi Y, Sugama Y, *et al.* Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs *in vitro* survival. IL-5 as an eosinophil chemotactic factor. *J Exp Med* 1988; **5**: 1737–1742.
- Teague TK, Marrack P, Kappler JW, Vella AT. IL-6 rescues resting mouse T cells from apoptosis. *J Immunol* 1997; **12**: 5791–5796.
- Cassatella MA, Guasparri I, Ceska M, Bazzoni F, Rossi F. Interferon-gamma inhibits interleukin-8 production by human polymorphonuclear leucocytes. *Immunology* 1993; **2**: 177–184.
- Purkerson JM, Isakson PC. Interleukin 5 (IL-5) provides a signal that is required in addition to IL-4 for isotype switching to immunoglobulin (Ig) G1 and IgE. *J Exp Med* 1992; **4**: 973–982.
- Punnonen J, Aversa G, Cocks BG, *et al.* Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. *Proc Natl Acad Sci USA* 1993; **8**: 3730–3734.
- Swain SL, Weinberg AD, English M, Huston G. IL-4 directs the development of Th2-like helper effectors. *J Immunol* 1990; **11**: 3796–3806.
- Peters SP, Zangrilli JG, Fish JE. Late phase allergic reactions. In: Middleton *et al.*, eds. *Allergy: principles and practice*. St Louis: Mosby, 1998: 342–355.
- Broide DH, Firestein GS. Endobronchial allergen challenge in asthma. Demonstration of cellular source of granulocyte macrophage colony-stimulating factor by *in situ* hybridization. *J Clin Invest* 1991; **3**: 1048–1053.
- Kay AB, Ying S, Varney V, *et al.* Messenger RNA expression of the cytokine gene cluster, interleukin 3 (IL-3), IL-4, IL-5, and granulocyte/macrophage colony-stimulating factor, in allergen-induced late-phase cutaneous reactions in atopic subjects. *J Exp Med* 1991; **3**: 775–778.
- Barata LT, Ying S, Meng Q, *et al.* IL-4- and IL-5-positive T lymphocytes, eosinophils, and mast cells in allergen-induced late-phase cutaneous reactions in atopic subjects. *J Allergy Clin Immunol* 1998; **2**: 222–230.
- Bentley AM, Meng Q, Robinson DS, Hamid Q, Kay AB, Durham SR. Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. *Am J Respir Cell Mol Biol* 1993; **1**: 35–42.
- Berin MC, Eckmann L, Broide DH, Kagnoff MF. Regulated production of the T helper 2-type T-cell chemoattractant TARC by human bronchial epithelial cells *in vitro* and in human lung xenografts. *Am J Respir Cell Mol Biol* 2001; **4**: 382–389.
- Bradding P, Feather IH, Wilson S, Holgate ST, Howarth PH. Cytokine immunoreactivity in seasonal rhinitis: regulation by a topical corticosteroid. *Am J Respir Crit Care Med* 1995; **6**: 1900–1906.
- Bradding P, Mediawake R, Feather IH, *et al.* TNF alpha is localized to nasal mucosal mast cells and is released in acute allergic rhinitis. *Clin Exp Allergy* 1995; **5**: 406–415.
- Braunstahl GJ, Overbeek SE, Kleinjan A, Prins JB, Hoogsteden HC, Fokkens WJ. Nasal allergen provocation induces adhesion molecule expression and tissue eosinophilia in upper and lower airways. *J Allergy Clin Immunol* 2001; **3**: 469–476.
- Brown JR, Kleimberg J, Marini M, Sun G, Bellini A, Mattoli S. Kinetics of eotaxin expression and its relationship to eosinophil accumulation and activation in bronchial biopsies and bronchoalveolar lavage (BAL) of asthmatic patients after allergen inhalation. *Clin Exp Immunol* 1998; **2**: 137–146.
- Calhoun WJ, Hinton KL, Kratzberg JJ. The effect of salmeterol on markers of airway inflammation following segmental allergen challenge. *Am J Respir Crit Care Med* 2001; **4**: 881–886.
- Cameron LA, Durham SR, Jacobson MR, *et al.* Expression of IL-4, Cepsilon RNA, and Iepsilon RNA in the nasal mucosa of patients with seasonal rhinitis: effect of topical corticosteroids. *J Allergy Clin Immunol* 1998; **3**: 330–336.
- Chakir J, Laviolette M, Turcotte H, Boutet M, Boulet LP. Cytokine expression in the lower airways of nonasthmatic subjects with allergic rhinitis: influence of natural allergen exposure. *J Allergy Clin Immunol* 2000; **5**: 904–910.
- Christodoulou P, Wright E, Frenkiel S, Luster A, Hamid Q. Monocyte chemotactic proteins in allergen-induced inflammation in the nasal mucosa: effect of topical corticosteroids. *J Allergy Clin Immunol* 1999; **6**: 1036–1044.
- de Blay F, Krieger P, Spirlet F, *et al.* Repeated inhalation of low doses of cat allergen that do not induce clinical symptoms increases bronchial hyperresponsiveness and eosinophil cationic protein levels. *Int Arch Allergy Immunol* 1999; **2**: 158–165.
- Diaz-Sanchez D, Jyrala M, Ng D, Nel A, Saxon A. *In vivo* nasal challenge with diesel exhaust particles enhances expression of the CC chemokines rantes, MIP-1alpha, and MCP-3 in humans. *Clin Immunol* 2000; **2**: 140–145.
- Diaz-Sanchez D, Tsiang A, Fleming J, Saxon A. Combined diesel exhaust particulate and ragweed allergen challenge markedly enhances human *in vivo* nasal ragweed-specific IgE and skews cytokine production to a T helper cell 2-type pattern. *J Immunol* 1997; **5**: 2406–2413.
- Djukanovic R, Feather I, Gratziau C, *et al.* Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms. *Thorax* 1996; **6**: 575–581.
- Durham SR, Walker SM, Varga EM, *et al.* Long-term clinical efficacy of grass-pollen immunotherapy. *N Engl J Med* 1999; **7**: 468–475.
- Durham SR, Ying S, Varney VA, *et al.* Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia. *J Immunol* 1992; **8**: 2390–2394.
- Durham SR, Gould HJ, Thienes CP, *et al.* Expression of epsilon germ-line gene transcripts and mRNA for the epsilon heavy chain of IgE in nasal B cells and the effects of topical corticosteroid. *Eur J Immunol* 1997; **11**: 2899–2906.
- Durham SR, Ying S, Varney VA, *et al.* Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. *J Allergy Clin Immunol* 1996; **6**: 1356–1365.
- Eldridge MW, Peden DB. Allergen provocation augments endotoxin-induced nasal inflammation in subjects with atopic asthma. *J Allergy Clin Immunol* 2000; **3**: 475–481.
- Fernvik E, Gronneberg R, Lundahl J, *et al.* Characterization of eosinophils and detection of eotaxin in skin chamber fluid after challenge with relevant allergen in patients with mild asthma. *Clin Exp Allergy* 1999; **11**: 1516–1525.
- Fernvik E, Hallden G, Lundahl J, *et al.* Allergen-induced accumulation of eosinophils and lymphocytes in skin chambers is associated with increased levels of interleukin-4 and sVCAM-1. *Allergy* 1999; **5**: 455–463.
- Ghaffar O, Laberge S, Jacobson MR, *et al.* IL-13 mRNA and immunoreactivity in allergen-induced rhinitis: comparison with IL-4 expression and modulation by topical glucocorticoid therapy. *Am J Respir Cell Mol Biol* 1997; **1**: 17–24.
- Ghaffar O, Christodoulou P, Lamkhioued B, *et al.* *In vivo* expression of signal transducer and activator of transcription factor 6 (STAT6) in nasal mucosa from atopic allergic rhinitis: effect of topical corticosteroids. *Clin Exp Allergy* 2000; **1**: 86–93.
- Gosset P, Tillie-Leblond I, Malaquin F, Durieu J, Wallaert B, Tonnel AB. Interleukin-8 secretion in patients with allergic rhinitis after an allergen challenge: interleukin-8 is not the main chemotactic factor present in nasal lavages. *Clin Exp Allergy* 1997; **4**: 379–388.
- Gosset P, Malaquin F, Delneste Y, *et al.* Interleukin-6 and interleukin-1 alpha production is associated with antigen-induced late nasal response. *J Allergy Clin Immunol* 1993; **6**: 878–890.
- Greiff L, Petersen H, Mattsson E, *et al.* Mucosal output of eotaxin in allergic rhinitis and its attenuation by topical glucocorticosteroid treatment. *Clin Exp Allergy* 2001; **8**: 1321–1327.

41. Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. *J Allergy Clin Immunol* 1997; **2**: 254–260.
42. Hasday JD, Meltzer SS, Moore WC, *et al.* Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics. *Am J Respir Crit Care Med* 2000; **4**: 1229–1236.
43. Haselden BM, Larche M, Meng Q, *et al.* Late asthmatic reactions provoked by intradermal injection of T-cell peptide epitopes are not associated with bronchial mucosal infiltration of eosinophils or TH2-type cells or with elevated concentrations of histamine or eicosanoids in bronchoalveolar fluid. *J Allergy Clin Immunol* 2001; **3**: 394–401.
44. Hoefakker S, Caubo M, van't Erve EH, *et al.* In vivo cytokine profiles in allergic and irritant contact dermatitis. *Contact Dermatitis* 1995; **4**: 258–266.
45. Holgate ST, Bodey KS, Janezic A, Frew AJ, Kaplan AP, Teran LM. Release of RANTES, MIP-1 alpha, and MCP-1 into asthmatic airways following endobronchial allergen challenge. *Am J Respir Crit Care Med* 1997; **5**: 1377–1383.
46. Howie SE, Aldridge RD, McVittie E, Forsey RJ, Sands C, Hunter JA. Epidermal keratinocyte production of interferon-gamma immunoreactive protein and mRNA is an early event in allergic contact dermatitis. *J Invest Dermatol* 1996; **6**: 1218–1223.
47. Huang SK, Xiao HQ, Kleine-Tebbe J, *et al.* IL-13 expression at the sites of allergen challenge in patients with asthma. *J Immunol* 1995; **5**: 2688–2694.
48. Jacobi HH, Poulsen LK, Reimert CM, *et al.* IL-8 and the activation of eosinophils and neutrophils following nasal allergen challenge. *Int Arch Allergy Immunol* 1998; **1**: 53–59.
49. Julius P, Luttmann W, Knoechel B, Kroegel C, Matthys H, Virchow JC Jr. CD69 surface expression on human lung eosinophils after segmental allergen provocation. *Eur Respir J* 1999; **6**: 1253–1259.
50. Kato M, Liu W, Hattori T, Nakashima I. Evidence of potential regulation by interleukin-4 of the soluble intercellular adhesion molecule 1 level in patients with seasonal allergic rhinitis under provocation by a small amount of natural allergen. *Ann Otol Rhinol Laryngol* 1998; **3**: 232–235.
51. Kelly EA, Rodriguez RR, Busse WW, Jarjour NN. The effect of segmental bronchoprovocation with allergen on airway lymphocyte function. *Am J Respir Crit Care Med* 1997; **5**: 1421–1428.
52. Khan LN, Kon OM, Macfarlane AJ, *et al.* Attenuation of the allergen-induced late asthmatic reaction by cyclosporin A is associated with inhibition of bronchial eosinophils, interleukin-5, granulocyte macrophage colony-stimulating factor, and eotaxin. *Am J Respir Crit Care Med* 2000; **4**: 1377–1382.
53. Kita H, Jorgensen RK, Reed CE, *et al.* Mechanism of topical glucocorticoid treatment of hay fever: IL-5 and eosinophil activation during natural allergen exposure are suppressed, but IL-4, IL-6, and IgE antibody production are unaffected. *J Allergy Clin Immunol* 2000; **3**: 521–529.
54. Kleinjan A, Holm AF, Dijkstra MD, *et al.* Preventive treatment of intranasal fluticasone propionate reduces cytokine mRNA expressing cells before and during a single nasal allergen provocation. *Clin Exp Allergy* 2000; **10**: 1476–1485.
55. Kleinjan A, Dijkstra MD, Boks SS, Severijnen LA, Mulder PG, Fokkens WJ. Increase in IL-8, IL-10, IL-13, and RANTES mRNA levels (in situ hybridization) in the nasal mucosa after nasal allergen provocation. *J Allergy Clin Immunol* 1999; **3**: 441–450.
56. Kroegel C, Julius P, Matthys H, Virchow JC Jr, Luttmann W. Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. *Eur Respir J* 1996; **5**: 899–904.
57. Krug N, Erpenbeck VJ, Balke K, *et al.* Cytokine profile of bronchoalveolar lavage-derived CD4(+), CD8(+), and gammadelta T cells in people with asthma after segmental allergen challenge. *Am J Respir Cell Mol Biol* 2001; **1**: 125–131.
58. Krug N, Cruikshank WW, Tschernig T, *et al.* Interleukin 16 and T-cell chemoattractant activity in bronchoalveolar lavage 24 hours after allergen challenge in asthma. *Am J Respir Crit Care Med* 2000; **1**: 105–111.
59. Laberge S, Pinsonneault S, Varga EM, *et al.* Increased expression of IL-16 immunoreactivity in bronchial mucosa after segmental allergen challenge in patients with asthma. *J Allergy Clin Immunol* 2000; **2**: 293–301.
60. Laberge S, Durham SR, Ghaffar O, *et al.* Expression of IL-16 in allergen-induced late-phase nasal responses and relation to topical glucocorticoid treatment. *J Allergy Clin Immunol* 1997; **4**: 569–574.
61. Lee CE, Neuland ME, Teaford HG, *et al.* Interleukin-6 is released in the cutaneous response to allergen challenge in atopic individuals. *J Allergy Clin Immunol* 1992; **5**: 1010–1020.
62. Lilly CM, Nakamura H, Belostotsky OI, *et al.* Eotaxin expression after segmental allergen challenge in subjects with atopic asthma. *Am J Respir Crit Care Med* 2001; **7**: 1669–1675.
63. Linden M, Svensson C, Andersson E, Andersson M, Greiff L, Persson CG. Immediate effect of topical budesonide on allergen challenge-induced nasal mucosal fluid levels of granulocyte-macrophage colony-stimulating factor and interleukin-5. *Am J Respir Crit Care Med* 2000; **5**: 1705–1708.
64. Linden M, Greiff L, Andersson M, *et al.* Nasal cytokines in common cold and allergic rhinitis. *Clin Exp Allergy* 1995; **2**: 166–172.
65. Liu MC, Proud D, Lichtenstein LM, *et al.* Effects of prednisone on the cellular responses and release of cytokines and mediators after segmental allergen challenge of asthmatic subjects. *J Allergy Clin Immunol* 2001; **1**: 29–38.
66. Massey W, Friedman B, Kato M, *et al.* Appearance of granulocyte-macrophage colony-stimulating factor activity at allergen-challenged cutaneous late-phase reaction sites. *J Immunol* 1993; **3**: 1084–1092.
67. Masuyama K, Till SJ, Jacobson MR, *et al.* Nasal eosinophilia and IL-5 mRNA expression in seasonal allergic rhinitis induced by natural allergen exposure: effect of topical corticosteroids. *J Allergy Clin Immunol* 1998; **4**: 610–617.
68. Masuyama K, Jacobson MR, Rak S, *et al.* Topical glucocorticosteroid (fluticasone propionate) inhibits cells expressing cytokine mRNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis. *Immunology* 1994; **2**: 192–199.
69. Minshall EM, Cameron L, Lavigne F, *et al.* Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis. *Am J Respir Cell Mol Biol* 1997; **6**: 683–690.
70. Moore WC, Hasday JD, Meltzer SS, Wisnewski PL, White B, Bleecker ER. Subjects with mild and moderate asthma respond to segmental allergen challenge with similar, reproducible, allergen-specific inflammation. *J Allergy Clin Immunol* 2001; **6**: 908–914.
71. Moqbel R, Ying S, Barkans J, *et al.* Identification of messenger RNA for IL-4 in human eosinophils with granule localization and release of the translated product. *J Immunol* 1995; **10**: 4939–4947.
72. Nakamura Y, Christodoulopoulos P, Cameron L, *et al.* Upregulation of the transcription factor GATA-3 in upper airway mucosa after in vivo and in vitro allergen challenge. *J Allergy Clin Immunol* 2000; **6**: 1146–1152.
73. Nasser SM, Ying S, Meng Q, Kay AB, Ewan PW. Interleukin-10 levels increase in cutaneous biopsies of patients undergoing wasp venom immunotherapy. *Eur J Immunol* 2001; **12**: 3704–3713.
74. Nocker RE, Out TA, Weller FR, Mul EP, Jansen HM, van der Zee JS. Influx of neutrophils into the airway lumen at 4 h after segmental allergen challenge in asthma. *Int Arch Allergy Immunol* 1999; **1**: 45–53.
75. Nonaka M, Nonaka R, Woolley K, *et al.* Distinct immunohistochemical localization of IL-4 in human inflamed airway tissues. IL-4 is localized to eosinophils in vivo and is released by peripheral blood eosinophils. *J Immunol* 1995; **6**: 3234–3244.
76. Nopp A, Hallden G, Lundahl J, *et al.* Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. *J Allergy Clin Immunol* 2000; **1**: 101–109.
77. Nouri-Aria KT, Irani AM, Jacobson MR, *et al.* Basophil recruitment and IL-4 production during human allergen-induced late asthma. *J Allergy Clin Immunol* 2001; **2**: 205–211.
78. Nouri-Aria KT, O'Brien F, Noble W, Jacobson MR, Rajakulasingam K, Durham SR. Cytokine expression during allergen-induced late nasal responses: IL-4 and IL-5 mRNA is expressed early (at 6 h) predominantly by eosinophils. *Clin Exp Allergy* 2000; **12**: 1709–1716.
79. Nouri-Aria KT, Masuyama K, Jacobson MR, *et al.* Granulocyte/macrophage colony stimulating factor in allergen-induced rhinitis: cellular localization, relation to tissue eosinophilia and influence of topical corticosteroid. *Int Arch Allergy Immunol* 1998; **4**: 248–254.
80. Peden DB, Setzer RW Jr, Devlin RB. Ozone exposure has both a priming effect on allergen-induced responses and an intrinsic inflammatory action in the nasal airways of perennially allergic asthmatics. *Am J Respir Crit Care Med* 1995; **5**: 1336–1345.
81. Prieto J, Van Der Ploeg I, Roquet A, *et al.* Cytokine mRNA expression in patients with mild allergic asthma following low dose or cumulative dose allergen provocation. *Clin Exp Allergy* 2001; **5**: 791–800.
82. Proud D, Reynolds CJ, Lichtenstein LM, Kagey-Sobotka A, Togias A. Intranasal salmeterol inhibits allergen-induced vascular permeability but not mast cell activation or cellular infiltration. *Clin Exp Allergy* 1998; **7**: 868–875.
83. Pullerits T, Linden A, Malmhall C, Lotvall J. Effect of seasonal allergen exposure on mucosal IL-16 and CD4+ cells in patients with allergic rhinitis. *Allergy* 2001; **9**: 871–877.
84. Rajakulasingam K, Hamid Q, O'Brien F, *et al.* RANTES in human allergen-induced rhinitis: cellular source and relation to tissue eosinophilia. *Am J Respir Crit Care Med* 1997; **2**: 696–703.
85. Raulf-Heimsoth M, Wirtz C, Papenfuss F, Baur X. Nasal lavage mediator profile and cellular composition of nasal brushing material during latex challenge tests. *Clin Exp Allergy* 2000; **1**: 110–121.
86. Robinson D, Hamid Q, Bentley A, Ying S, Kay AB, Durham SR. Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. *J Allergy Clin Immunol* 1993; **2**: 313–324.

87. Robinson DS, Tscopoulos A, Meng Q, Durham S, Kay AB, Hamid Q. Increased interleukin-10 messenger RNA expression in atopic allergy and asthma. *Am J Respir Cell Mol Biol* 1996; **2**: 113–117.
88. Saengpanich S, Assanasen P, deTineo M, Haney L, Naclerio RM, Baroody FM. Effects of intranasal azelastine on the response to nasal allergen challenge. *Laryngoscope* 2002; **1**: 47–52.
89. Sim TC, Reece LM, Hilsmeier KA, Grant JA, Alam R. Secretion of chemokines and other cytokines in allergen-induced nasal responses: inhibition by topical steroid treatment. *Am J Respir Crit Care Med* 1995; **3**: 927–933.
90. Sur S, Kita H, Gleich GJ, Chenier TC, Hunt LW. Eosinophil recruitment is associated with IL-5, but not with RANTES, twenty-four hours after allergen challenge. *J Allergy Clin Immunol* 1996; **6**: 1272–1278.
91. Taborda-Barata L, Jacobson M, Walker S, et al. Effect of cetirizine and prednisolone on cellular infiltration and cytokine mRNA expression during allergen-induced late cutaneous responses. *Clin Exp Allergy* 1996; **1**: 68–78.
92. Terada N, Hamano N, Kim WJ, et al. The kinetics of allergen-induced eotaxin level in nasal lavage fluid: its key role in eosinophil recruitment in nasal mucosa. *Am J Respir Crit Care Med* 2001; **4**: 575–579.
93. Teran LM, Carroll MP, Shute JK, Holgate ST. Interleukin 5 release into asthmatic airways 4 and 24 hours after endobronchial allergen challenge: its relationship with eosinophil recruitment. *Cytokine* 1999; **7**: 518–522.
94. Teran LM, Carroll M, Frew AJ, et al. Neutrophil influx and interleukin-8 release after segmental allergen or saline challenge in asthmatics. *Int Arch Allergy Immunol* 1995; **1–3**: 374–375.
95. Teran LM, Noso N, Carroll M, Davies DE, Holgate S, Schroder JM. Eosinophil recruitment following allergen challenge is associated with the release of the chemokine RANTES into asthmatic airways. *J Immunol* 1996; **4**: 1806–1812.
96. Teran LM, Carroll MP, Frew AJ, et al. Leukocyte recruitment after local endobronchial allergen challenge in asthma. Relationship to procedure and to airway interleukin-8 release. *Am J Respir Crit Care Med* 1996; **2**: 469–476.
97. Thepen T, Langeveld-Wildschut EG, Bihari IC, et al. Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study. *J Allergy Clin Immunol* 1996; **3**: 828–837.
98. Thomassen MJ, Raychaudhuri B, Dweik RA, et al. Nitric oxide regulation of asthmatic airway inflammation with segmental allergen challenge. *J Allergy Clin Immunol* 1999; **6**: 1174–1182.
99. Tscopoulos A, Hamid Q, Haczk A, et al. Kinetics of cell infiltration and cytokine messenger RNA expression after intradermal challenge with allergen and tuberculin in the same atopic individuals. *J Allergy Clin Immunol* 1994; **4**: 764–772.
100. Varney VA, Hamid QA, Gaga M, et al. Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. *J Clin Invest* 1993; **2**: 644–651.
101. Virchow JC Jr, Walker C, Hafner D, et al. T cells and cytokines in bronchoalveolar lavage fluid after segmental allergen provocation in atopic asthma. *Am J Respir Crit Care Med* 1995; **4**: 960–968.
102. Virchow JC Jr, Julius P, Matthys H, Kroegel C, Luttmann W. CD14 expression and soluble CD14 after segmental allergen provocation in atopic asthma. *Eur Respir J* 1998; **2**: 317–323.
103. Wachholz PA, Nouri-Aria KT, Wilson DR, et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. *Immunology* 2002; **1**: 56–62.
104. Wang M, Saxon A, Diaz-Sanchez D. Early IL-4 production driving Th2 differentiation in a human in vivo allergic model is mast cell derived. *Clin Immunol* 1999; **1**: 47–54.
105. Wang JH, Duddle J, Devalia JL, Davies RJ. Nitrogen dioxide increases eosinophil activation in the early-phase response to nasal allergen provocation. *Int Arch Allergy Immunol* 1995; **1–3**: 103–105.
106. Wilson DR, Nouri-Aria KT, Walker SM, et al. Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season. *J Allergy Clin Immunol* 2001; **6**: 971–976.
107. Woolley KL, Adelroth E, Woolley MJ, et al. Interleukin-3 in bronchial biopsies from nonasthmatics and patients with mild and allergen-induced asthma. *Am J Respir Crit Care Med* 1996; **1**: 350–355.
108. Woolley KL, Adelroth E, Woolley MJ, Ellis R, Jordana M, O'Byrne PM. Effects of allergen challenge on eosinophils, eosinophil cationic protein, and granulocyte-macrophage colony-stimulating factor in mild asthma. *Am J Respir Crit Care Med* 1995; **6**: 1915–1924.
109. Wright ED, Christodoulou P, Frenkiel S, Hamid Q. Expression of interleukin (IL)-12 (p40) and IL-12 (beta 2) receptors in allergic rhinitis and chronic sinusitis. *Clin Exp Allergy* 1999; **10**: 1320–1325.
110. Ying S, Meng Q, Barata LT, Robinson DS, Durham SR, Kay AB. Associations between IL-13 and IL-4 (mRNA and protein), vascular cell adhesion molecule-1 expression, and the infiltration of eosinophils, macrophages, and T cells in allergen-induced late-phase cutaneous reactions in atopic subjects. *J Immunol* 1997; **10**: 5050–5057.
111. Ying S, Taborda-Barata L, Meng Q, Humbert M, Kay AB. The kinetics of allergen-induced transcription of messenger RNA for monocyte chemoattractant protein-3 and RANTES in the skin of human atopic subjects: relationship to eosinophil, T cell, and macrophage recruitment. *J Exp Med* 1995; **6**: 2153–2159.
112. Ying S, Kikuchi Y, Meng Q, Kay AB, Kaplan AP. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. *J Allergy Clin Immunol* 2002; **4**: 694–700.
113. Ying S, Meng Q, Taborda-Barata L, et al. Human eosinophils express messenger RNA encoding RANTES and store and release biologically active RANTES protein. *Eur J Immunol* 1996; **1**: 70–76.
114. Ying S, Meng Q, Barata LT, Kay AB. Macrophage inflammatory protein-1alpha and C-C chemokine receptor-1 in allergen-induced skin late-phase reactions: relationship to macrophages, neutrophils, basophils, eosinophils and T lymphocytes. *Clin Exp Allergy* 2001; **11**: 1724–1731.
115. Ying S, Robinson DS, Varney V, et al. TNF alpha mRNA expression in allergic inflammation. *Clin Exp Allergy* 1991; **6**: 745–750.
116. Ying S, Durham SR, Jacobson MR, et al. T lymphocytes and mast cells express messenger RNA for interleukin-4 in the nasal mucosa in allergen-induced rhinitis. *Immunology* 1994; **2**: 200–206.
117. Ying S, Durham SR, Barkans J, et al. T cells are the principal source of interleukin-5 mRNA in allergen-induced rhinitis. *Am J Respir Cell Mol Biol* 1993; **4**: 356–360.
118. Zweiman B, Kaplan AP, Tong L, Moskovitz AR. Cytokine levels and inflammatory responses in developing late-phase allergic reactions in the skin. *J Allergy Clin Immunol* 1997; **1**: 104–109.
119. Alvarez-Puebla MJ, Olaguibel-Rivera JM, Urbiola-Marcilla E, Garcia BE, Tabar-Purroy AI. Determinants of allergen-induced late bronchial responses in mild asthmatics. *Chest* 2001; **1**: 120–127.
120. Baroody FM, Rouadi P, Driscoll PV, Bochner BS, Naclerio RM. Intranasal beclomethasone reduces allergen-induced symptoms and superficial mucosal eosinophilia without affecting submucosal inflammation. *Am J Respir Crit Care Med* 1998; **3**: 899–906.
121. Berkman N, Ohnona S, Chung FK, Breuer R. Eotaxin-3 but not eotaxin gene expression is upregulated in asthmatics 24 hours after allergen challenge. *Am J Respir Cell Mol Biol* 2001; **6**: 682–687.
122. Broide DH, Paine MM, Firestein GS. Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. *J Clin Invest* 1992; **4**: 1414–1424.
123. Cameron L, Christodoulou P, Lavigne F, et al. Evidence for local eosinophil differentiation within allergic nasal mucosa: inhibition with soluble IL-5 receptor. *J Immunol* 2000; **3**: 1538–1545.
124. Cameron L, Hamid Q, Wright E, et al. Local synthesis of epsilon germline gene transcripts, IL-4, and IL-13 in allergic nasal mucosa after ex vivo allergen exposure. *J Allergy Clin Immunol* 2000; **1**: 46–52.
125. Diaz-Sanchez D, Tsien A, Fleming J, Saxon A. Effect of topical fluticasone propionate on the mucosal allergic response induced by ragweed allergen and diesel exhaust particle challenge. *Clin Immunol* 1999; **3**: 313–322.
126. Djukanovic R, Finnerty JP, Lee C, Wilson S, Madden J, Holgate ST. The effects of theophylline on mucosal inflammation in asthmatic airways: biopsy results. *Eur Respir J* 1995; **5**: 831–833.
127. Evans DJ, Barnes PJ, Spaethe SM, van Alstyne EL, Mitchell MI, O'Connor BJ. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. *Thorax* 1996; **12**: 1178–1184.
128. Frew AJ, Teran LM, Madden J, et al. Cellular changes 24 hours after endobronchial allergen challenge in asthma. *Int Arch Allergy Immunol* 1995; **1–3**: 376–377.
129. Gaglani B, Borish L, Bartelson BL, Buchmeier A, Keller L, Nelson HS. Nasal immunotherapy in weed-induced allergic rhinitis. *Ann Allergy Asthma Immunol* 1997; **3**: 259–265.
130. Gosset P, Tscopoulos A, Wallaert B, et al. Increased secretion of tumor necrosis factor alpha and interleukin-6 by alveolar macrophages consecutive to the development of the late asthmatic reaction. *J Allergy Clin Immunol* 1991; **4**: 561–571.
131. Gratziau C, Carroll M, Montefort S, Teran L, Howarth PH, Holgate ST. Inflammatory and T-cell profile of asthmatic airways 6 hours after local allergen provocation. *Am J Respir Crit Care Med* 1996; **2**: 515–520.
132. Hidi R, Riches V, Al-Ali M, et al. Role of B7-CD28/CTLA-4 costimulation and NF-kappa B in allergen-induced T cell chemotaxis by IL-16 and RANTES. *J Immunol* 2000; **1**: 412–418.
133. Hiltermann TJ, de Bruijne CR, Stolk J, et al. Effects of photochemical air pollution and allergen exposure on upper respiratory tract inflammation in asthmatics. *Am J Respir Crit Care Med* 1997; **6**: 1765–1772.
134. Jaffar Z, Roberts K, Pandit A, Linsley P, Djukanovic R, Holgate S. B7 costimulation is required for IL-5 and IL-13 secretion by bronchial biopsy tissue of atopic asthmatic subjects in response to allergen stimulation. *Am J Respir Cell Mol Biol* 1999; **1**: 153–162.
135. Jaffar ZH, Stanciu L, Pandit A, Lordan J, Holgate ST, Roberts K. Essential role for both CD80 and CD86 costimulation, but not CD40 interactions, in allergen-induced Th2 cytokine production from asthmatic bronchial tissue: role for alphabeta, but not gammadelta, T cells. *J Immunol* 1999; **11**: 6283–6291.

136. Jahnsen FL, Lund-Johansen F, Dunne JF, Farkas L, Haye R, Brandtzaeg P. Experimentally induced recruitment of plasmacytoid (CD123^{high}) dendritic cells in human nasal allergy. *J Immunol* 2000; **7**: 4062–4068.
137. Kawaguchi M, Onuchic LF, Li XD, *et al.* Identification of a novel cytokine, ML-1, and its expression in subjects with asthma. *J Immunol* 2001; **8**: 4430–4435.
138. Kelly EA, Busse WW, Jarjour NN. Inhaled budesonide decreases airway inflammatory response to allergen. *Am J Respir Crit Care Med* 2000; **3**: 883–890.
139. Krishnaswamy G, Liu MC, Su SN, *et al.* Analysis of cytokine transcripts in the bronchoalveolar lavage cells of patients with asthma. *Am J Respir Cell Mol Biol* 1993; **3**: 279–286.
140. Langeveld-Wildschut EG, Bruijnzeel PL, Mudde GC, *et al.* Clinical and immunologic variables in skin of patients with atopic eczema and either positive or negative atopy patch test reactions. *J Allergy Clin Immunol* 2000; **5**: 1008–1016.
141. Maestrelli P, Occari P, Turato G, *et al.* Expression of interleukin (IL)-4 and IL-5 proteins in asthma induced by toluene diisocyanate (TDI). *Clin Exp Allergy* 1997; **11**: 1292–1364.
142. Panina-Bordignon P, Papi A, Mariani M, *et al.* The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics. *J Clin Invest* 2001; **11**: 1357–1364.
143. Pawankar RU, Okuda M, Hasegawa S, *et al.* Interleukin-13 expression in the nasal mucosa of perennial allergic rhinitis. *Am J Respir Crit Care Med* 1995; **6**: 2059–2067.
144. Peebles RS Jr, Wagner EM, Liu MC, Proud D, Hamilton RG, Togias A. Allergen-induced changes in airway responsiveness are not related to indices of airway edema. *J Allergy Clin Immunol* 2001; **5**: 805–811.
145. Prieto J, Lensmar C, Roquet A, *et al.* Increased interleukin-13 mRNA expression in bronchoalveolar lavage cells of atopic patients with mild asthma after repeated low-dose allergen provocations. *Respir Med* 2000; **8**: 806–814.
146. Saarinen JV, Harvima RJ, Naukkarinen A, Horsmanheimo M, Harvima IT. Interleukin-4-positive mast cells are highly associated with the extent of immediate allergic wheal reaction in the skin. *Allergy* 2001; **1**: 58–64.
147. Schroeder JT, Lichtenstein LM, Roche EM, Xiao H, Liu MC. IL-4 production by human basophils found in the lung following segmental allergen challenge. *J Allergy Clin Immunol* 2001; **2**: 265–271.
148. Tscopoulos A, Hamid Q, Varney V, *et al.* Preferential messenger RNA expression of Th1-type cells (IFN- γ +, IL-2+) in classical delayed-type (tuberculin) hypersensitivity reactions in human skin. *J Immunol* 1992; **7**: 2058–2061.
149. Wang JH, Devalia JL, Duddle JM, Hamilton SA, Davies RJ. Effect of six-hour exposure to nitrogen dioxide on early-phase nasal response to allergen challenge in patients with a history of seasonal allergic rhinitis. *J Allergy Clin Immunol* 1995; **5**: 669–676.
150. Wills-Karp M, Luyimbazi J, Xu X, *et al.* Interleukin-13: central mediator of allergic asthma. *Science* 1998; **5397**: 2258–2261.
151. Wright ED, Christodoulou P, Small P, Frenkiel S, Hamid Q. Th-2 type cytokine receptors in allergic rhinitis and in response to topical steroids. *Laryngoscope* 1999; **4**: 551–556.
152. Yamada N, Wakugawa M, Kuwata S, Nakagawa H, Tamaki K. Changes in eosinophil and leukocyte infiltration and expression of IL-6 and IL-7 messenger RNA in mite allergen patch test reactions in atopic dermatitis. *J Allergy Clin Immunol* 1996; **6**: S201–S206.
153. Yamada N, Wakugawa M, Kuwata S, Yoshida T, Nakagawa H. Chronologic analysis of in situ cytokine expression in mite allergen-induced dermatitis in atopic subjects. *J Allergy Clin Immunol* 1995; **6**: 1069–1075.
154. Becherel PA, Chosidow O, Le Goff L, *et al.* Inducible nitric oxide synthase and proinflammatory cytokine expression by human keratinocytes during acute urticaria. *Mol Med* 1997; **10**: 686–694.
155. Karlsson MG, Davidsson A, Viale G, Graziani D, Hellquist HB. Nasal messenger RNA expression of interleukins 2, 4, and 5 in patients with allergic rhinitis. *Diagnosis Mol Pathol* 1995; **2**: 85–92.
156. Kato M, Liu MC, Stealey BA, *et al.* Production of granulocyte/macrophage colony-stimulating factor in human airways during allergen-induced late-phase reactions in atopic subjects. *Lymphokine Cytokine Res* 1992; **6**: 287–292.
157. Sur S, Gleich GJ, Offord KP, *et al.* Allergen challenge in asthma: association of eosinophils and lymphocytes with interleukin-5. *Allergy* 1995; **11**: 891–898.
158. Tang C, Rolland JM, Ward C, Quan B, Walters EH. Allergen-induced airway reactions in atopic asthmatics correlate with allergen-specific IL-5 response by BAL cells. *Respirology* 1997; **1**: 45–55.
159. Metcalfe DD, Baram D, Mekori YA. Mast cells. *Physiol Rev* 1997; **4**: 1033–1079.
160. Walsh LJ, Trinchieri G, Waldorf HA, Whitaker D, Murphy GF. Human dermal mast cells contain and release tumor necrosis factor α , which induces endothelial leukocyte adhesion molecule 1. *Proc Natl Acad Sci USA* 1991; **10**: 4220–4224.
161. Bradding P, Feather IH, Howarth PH, *et al.* Interleukin 4 is localized to and released by human mast cells. *J Exp Med* 1992; **5**: 1381–1386.
162. Nouri-Aria KT, Masuyama K, Jacobson MR, *et al.* Granulocyte/macrophage-colony stimulating factor in allergen-induced rhinitis: cellular localization, relation to tissue eosinophilia and influence of topical corticosteroid. *Int Arch Allergy Immunol* 1998; **4**: 248–254.
163. Marini M, Vittori E, Hollemborg J, Mattoli S. Expression of the potent inflammatory cytokines, granulocyte-macrophage-colony-stimulating factor and interleukin-6 and interleukin-8, in bronchial epithelial cells of patients with asthma. *J Allergy Clin Immunol* 1992; **5**: 1001–1009.
164. Metcalf D. The granulocyte-macrophage colony-stimulating factors. *Science* 1985; **4708**: 16–22.
165. Silberstein DS, Owen WF, Gasson JC, *et al.* Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. *J Immunol* 1986; **10**: 3290–3294.
166. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G. Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. *Cancer Res* 2000; **12**: 3239–3246.
167. Nguyen CL, Bui JT, Demcheva M, Vournakis JN, Cole DJ, Gillanders WE. Sustained release of granulocyte-macrophage colony-stimulating factor from a modular peptide-based cancer vaccine alters vaccine microenvironment and enhances the antigen-specific T-cell response. *J Immunother* 2001; **5**: 420–429.
168. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. *Nature* 1998; **6673**: 245–252.
169. Shortman K, Heath WR. Immunity or tolerance? That is the question for dendritic cells. *Nat Immunol* 2001; **11**: 988–989.
170. Albert ML, Jegathesan M, Darnell RB. Dendritic cell maturation is required for the cross-tolerization of CD8+ T cells. *Nat Immunol* 2001; **11**: 1010–1017.
171. Funachi M, Yoo BS, Nozaki Y, *et al.* Dysregulation of the granulocyte-macrophage colony-stimulating factor receptor is one of the causes of defective expression of CD80 antigen in systemic lupus erythematosus. *Lupus* 2002; **5**: 317–321.
172. Kotsimbos AT, Humbert M, Minshall E, *et al.* Upregulation of alpha GM-CSF-receptor in nonatopic asthma but not in atopic asthma. *J Allergy Clin Immunol* 1997; **5**: 666–672.
173. Dirksen U, Hattenhorst U, Schneider P, *et al.* Defective expression of granulocyte-macrophage colony-stimulating factor/interleukin-3/interleukin-5 receptor common beta chain in children with acute myeloid leukemia associated with respiratory failure. *Blood* 1998; **4**: 1097–1103.
174. Trapnell BC, Whitsett JA. GM-CSF regulates pulmonary surfactant homeostasis and alveolar macrophage-mediated innate host defense. *Annu Rev Physiol* 2002; **64**: 775–802.
175. Ying S, Robinson DS, Meng Q, *et al.* Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. *Eur J Immunol* 1997; **12**: 3507–3516.
176. Yano K, Yamaguchi M, de Mora F, *et al.* Production of macrophage inflammatory protein-1 α by human mast cells: increased anti-IgE-dependent secretion after IgE-dependent enhancement of mast cell IgE-binding ability. *Lab Invest* 1997; **2**: 185–193.
177. Ying S, Robinson DS, Meng Q, *et al.* C-C chemokines in allergen-induced late-phase cutaneous responses in atopic subjects: association of eotaxin with early 6-hour eosinophils, and of eotaxin-2 and monocyte chemoattractant protein-4 with the later 24-hour tissue eosinophilia, and relationship to basophils and other C-C chemokines (monocyte chemoattractant protein-3 and RANTES). *J Immunol* 1999; **7**: 3976–3984.
178. Ying S, Meng Q, Barata LT, Kay AB. Macrophage inflammatory protein-1 α and C-C chemokine receptor-1 in allergen-induced skin late-phase reactions: relationship to macrophages, neutrophils, basophils, eosinophils and T lymphocytes. *Clin Exp Allergy* 2001; **11**: 1724–1731.
179. Andrew DP, Chang MS, McNinch J, *et al.* STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. *J Immunol* 1998; **9**: 5027–5038.
180. Mantovani A, Gray PA, Van Damme J, Sozzani S. Macrophage-derived chemokine (MDC). *J Leukoc Biol* 2000; **3**: 400–404.
181. Salvi SS, Babu KS, Holgate ST. Is asthma really due to a polarized T cell response toward a helper T cell type 2 phenotype? *Am J Respir Crit Care Med* 2001; **8**: 1343–1346.
182. Boushey HA, Fahy JV. Targeting cytokines in asthma therapy: round one. *Lancet* 2000; **9248**: 2114–2116.
183. Leckie MJ, ten Brinke A, Khan J, *et al.* Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. *Lancet* 2000; **9248**: 2144–2148.

Received 7 February 2003
Accepted 2 July 2003